1. Centers for Disease Control and Prevention, & U. S. Department of Human and Health Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. [cited 2019 Nov 3]. Available from https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf.
2. Centers for Disease Control and Prevention. Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. 2017. [cited 2019 Nov 3]. Available from https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html.
3. World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: Recommendations for a public health approach. 2014. [cited 2019 Dec 3]. Available from https://apps.who.int/iris/bitstream/handle/10665/145719/9789241508193_eng.pdf;jsessionid=95884E0BA394F739B5D92D056E5B912F?sequence=1.
4. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35(5):519–25. https://doi.org/10.1097/00126334-200404150-00010.
5. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004;18:2065–73 [PubMed: 15577628].